Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.36 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | CASP1 | P29466 | 6/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 4/20 | 0.32 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199261 | 1.00 | ITGB1 (0.36) | ITGB1ITGA4ELANECASP1ITGB7 | |
| SCHEMBL10199404 | 0.87 | CASP1 (0.42) | ELANECASP1CTSSIL1B | |
| SCHEMBL10247759 | 0.87 | CASP1 (0.42) | ELANECASP1CTSSIL1B | |
| SCHEMBL647783 | 0.87 | CASP1 (0.41) | ITGB1ITGA4ELANECASP1IL1B | |
| SCHEMBL644683 | 0.87 | CASP1 (0.41) | ITGB1ITGA4ELANECASP1IL1B | |
| SCHEMBL13139539 | 0.87 | CASP1 (0.41) | ITGB1ITGA4ELANECASP1IL1B | |
| SCHEMBL648084 | 0.79 | CASP1 (0.59) | CASP1IL1B | |
| SCHEMBL645261 | 0.79 | CASP1 (0.59) | CASP1IL1B | |
| SCHEMBL7740043 | 0.78 | LCK (0.35) | CASP1IL1B | |
| SCHEMBL645660 | 0.73 | CASP1 (0.43) | ITGB1ITGA4CASP1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ITGB1 1654/4885ITGA4 3642/4885ELANE 733/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | ITGB1 2331/4885ITGA4 3912/4885ELANE 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.